▲ +196.42% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $10.29, with a high forecast of $18.00 and a low forecast of $3.00. The average price target represents a 196.42% upside from the last price of $3.47.
The current consensus among 7 polled investment analysts is to hold stock in Akebia Therapeutics. This rating has held steady since April 2020, when it changed from a Buy consensus rating.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.